The Pennine Acute Hospitals
NHS Trust Formulary
 
back
10 Musculoskeletal and joint diseases
10-01-03 Biologics
Biologics can be used, without prior funding approval, according to GMMMG-approved pathways: Harmonised Biologics Pathway for Rheumatoid Arthritis and Harmonised Biologics Pathway for Ankylosing Spondylitis and Psoriatic Arthritis
Abatacept
Formulary

Intravenous infusion


Red View adult BNF  View SPC online  View childrens BNF
Adalimumab  Amgevita®) (BIOSIMILAR
Formulary

Subcutaneous Injection


Red View adult BNF  View SPC online  View childrens BNF
Adalimumab Humira®
Formulary

Subcutaneous Injection

Link  MHRA Drug Safety Update, April 2014: TNF alpha inhibitors: Risk of tuberculosis - screen all patients before starting treatment and monitor them closely.
Link  NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
 

Red View adult BNF  View SPC online  View childrens BNF
Certolizumab Pegol
Formulary

Subcutaneous Injection

Link  MHRA Drug Safety Update, April 2014: TNF alpha inhibitors: Risk of tuberculosis - screen all patients before starting treatment and monitor them closely.
Link  NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Link  NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
 

Red View adult BNF  View SPC online  View childrens BNF
Etanercept Benepali®
Formulary

Subcutaneous Injection





  • New patients only


Link  GMMMG Guidance: Prescribing Biosimilar Biologic Medicines
Link  GMMMG Recommendation: Etanercept biosimilar (Benepali)
Link  UKMi Q&A: What are biosimilar medicinal products?
 

Red View adult BNF  View SPC online  View childrens BNF
Etanercept Enbrel®
Formulary

Subcutaneous Injection



Link  MHRA Drug Safety Update, April 2014: TNF alpha inhibitors: Risk of tuberculosis - screen all patients before starting treatment and monitor them closely.
Link  NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Link  NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Link  NICE TA35: Arthritis (juvenile idiopathic) - etanercept
 

Red View adult BNF  View SPC online  View childrens BNF
Golimumab
Formulary

Subcutaneous Injection

Link  MHRA Drug Safety Update, April 2014: TNF alpha inhibitors: Risk of tuberculosis - screen all patients before starting treatment and monitor them closely.
Link  NICE TA220: Psoriatic arthritis - golimumab
Link  NICE TA225: Rheumatoid arthritis - golimumab
Link  NICE TA233: Ankylosing spondylitis - golimumab
 

Red View adult BNF  View SPC online  View childrens BNF
Infliximab
Formulary
Intravenous Infusion
Link  MHRA Drug Safety Update, April 2014: TNF alpha inhibitors: Risk of tuberculosis - screen all patients before starting treatment and monitor them closely.
Link  NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Link  NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
 

Red View adult BNF  View SPC online  View childrens BNF
Rituximab
Formulary
Intravenous Infusion
Link  MHRA Drug Safety Update December 2009: Rituximab: progressive multifocal leukoencephalopathy in a patient without prior treatment for RA
Link  MHRA Drug Safety Update, December 2013: Rituximab: screen for hepatitis B virus before treatment
Link  NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
 

Red View adult BNF  View SPC online  View childrens BNF
Sarilumab Kavzara®
Formulary

Pre-filled syringe or pen

Link  NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
 

Red View adult BNF  View SPC online  View childrens BNF
Secukinumab Cosentyx®
Formulary

Pre-filled syringe

Link  NICE TA445: Secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
 

Red View adult BNF  View SPC online  View childrens BNF
Tocilizumab
Formulary
Intravenous preparation ONLY

(Subcutaneous preparation is currently non-formulary)
Link  NICE TA198: Rheumatoid arthritis - tocilizumab
Link  NICE TA518: Tocilizumab for treating giant cell arteritis
 

Red View adult BNF  View SPC online  View childrens BNF
Ustekinumab
Formulary

Subcutaneous Injection


Approved for use as per NICE TA340, i.e.:

Ustekinumab is recommended as an option, alone or in combination with methotrexate, for treating active psoriatic arthritis in adults only when:
• treatment with TNF alpha inhibitors is contraindicated but would otherwise be considered (as described in NICE guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis and golimumab for the treatment of psoriatic arthritis)
• or the person has had treatment with 1 or more TNF–alpha inhibitors.

Ustekinumab is recommended only if the company provides the 90mg dose of ustekinumab for people who weigh more than 100 kg at the same cost as the 45mg dose, as agreed in the patient access scheme.

Link  NICE TA340: Ustekinumab for treating active psoriatic arthritis
 

Red View adult BNF  View SPC online  View childrens BNF
Belimumab
Non Formulary
GMMMG recommends that belimumab may be used only when commissioned by NHS England

Red View adult BNF  View SPC online  View childrens BNF
Tocilizumab
Non Formulary
Subcutaneous injection

Supplied via homecare arrangements


Red View adult BNF  View SPC online  View childrens BNF